Faculty Profiles - NAGAO Shoji

Papers - NAGAO Shoji

Division display 121 - 128 of about 128 ／ All the affair displays >>

Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. Reviewed

Satoru Nagase, Yoshiki Inoue, Naohiko Umesaki, Daisuke Aoki, Masatsugu Ueda, Hideki Sakamoto, Shigemitsu Kobayashi, Ryo Kitagawa, Takafumi Toita, Shoji Nagao, Kiyoshi Hasegawa, Ichio Fukasawa, Keiichi Fujiwara, Yoh Watanabe, Kiyoshi Ito, Hitoshi Niikura, Tsuyoshi Iwasaka, Kazunori Ochiai, Hidetaka Katabuchi, Toshiharu Kamura, Ikuo Konishi, Noriaki Sakuragi, Tadao Tanaka, Yasuo Hirai, Yuji Hiramatsu, Makio Mukai, Hiroyuki Yoshikawa, Tadao Takano, Kosuke Yoshinaga, Takeo Otsuki, Michiko Sakuma, Noriyuki Inaba, Yasuhiro Udagawa, Nobuo Yaegashi

International journal of clinical oncology 15 ( 2 ) 117 - 24 2010.4

Language：English Publishing type：Research paper (scientific journal)

Clinical practice guidelines for gynecologic cancers have been published by the National Comprehensive Cancer Network and the National Cancer Institute. Whereas these guidelines form the basis for the standard of care for gynecologic malignancies in the United States, it has proven difficult to institute them in Japan due to differences in patient characteristics, health-care delivery systems, and insurance programs. Therefore, evidence-based guidelines for treating cervical cancer specifically in Japan have been under development. The Guidelines Formulation Committee and Evaluation Committee were independently established within the Committee for Treatment Guidelines for Cervical Cancer. Opinions from within and outside the Japan Society of Gynecologic Oncology (JSGO) were incorporated into the final draft, and the guidelines were published after approval by the JSGO. These guidelines are composed of ten chapters and comprise three algorithms. Each chapter consists of a clinical question, recommendations, background, objectives, explanations, and references. The objective of these guidelines is to clearly delineate the standard of care for cervical cancer treatment in Japan in order to ensure equitable care for all Japanese women diagnosed with cervical cancer.

DOI： 10.1007/s10147-010-0061-x

PubMed

researchmap

Splenectomy during Secondary Cytoreductive Surgery for Epithelial Ovarian Cancer Reviewed International journal

Jitti Hanprasertpong, Rie Ohishi, Norihiro Iwasa, Shoji Nagao, Kojun Okamoto, Keiichi Fujiwara

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION 11 ( 2 ) 413 - 416 2010

Language：English Publishing type：Research paper (scientific journal) Publisher：ASIAN PACIFIC ORGANIZATION CANCER PREVENTION

Splenic metastasis from ovarian cancer is unusual. Most splenic metastases are encountered in the setting of widespread visceral metastases. We present 6 cases of splenic metastasis of epithelial ovarian cancer. Three cases underwent a splenectomy as a part of interval debulking surgery, and the rest received a splenectomy as a surgery for recurrent disease. The splenectomies were well-tolerated in all patients and no serious morbidity or mortality resulted. Only one patient experienced a transient elevation in platelet count.

Web of Science

PubMed

researchmap

NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer Reviewed

S. Nagao, K. Fujiwara, R. Ohishi, Y. Nakanishi, N. Iwasa, M. Shimizu, T. Goto, K. Shimoya

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 18 ( 6 ) 1210 - 1214 2008.11

Language：English Publishing type：Research paper (scientific journal) Publisher：LIPPINCOTT WILLIAMS & WILKINS

Nagao S, Fujiwara K, Ohishi R, Nakanishi Y, Iwasa N, Shimizu M, Goto T, Shimoya K. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer. Int J Gynecol Cancer 2008;18:1210-1214.
The objective of this study was to retrospectively assess the efficacy and safety of combination chemotherapy of intraperitoneal (IP) carboplatin and intravenous (IV) paclitaxel in suboptimally debulked ovarian cancer. Between March 1998 and March 2006, 44 patients with histologically confirmed epithelial ovarian carcinoma or peritoneal carcinoma with a residual mass greater than 1 cm received combination chemotherapy of IV paclitaxel and IP carboplatin. Administration of IV paclitaxel at 175 mg/m(2) immediately followed by IP carboplatin at an area under the curve of 6 was scheduled every 3 weeks for at least six cycles. The diagnosis and stage were ovarian carcinoma stage II in 8, III in 25, and IV in 6 cases, and peritoneal carcinoma stage III in 5 cases. Eighty-three percent of patients completed more than six cycles of chemotherapy. The incidences of grade 3/4 hematologic toxicities were 41 (93%) for neutrocytopenia, 10 (41%) for thrombocytopenia, and 18 (23%) for anemia. Observed grade 3/4 nonhematologic toxicities were 1 (2%) for allergy, 1 (2%) for fatigue, 1 (2%) for vomiting, 1 (2%) for liver dysfunction, and 4 (9%) for peripheral neuropathy. Two patients (5%) encountered catheter problems (one obstruction and one infection). Overall response rate was 80% (16 complete response, 19 partial response, 3 stable disease, and 6 progressive disease). Median progression-free survival and overall survival were 24 and 31 months, respectively. Combination chemotherapy of IP carboplatin and IV paclitaxel is effective and safe in suboptimally debulked ovarian cancer, and further evaluation is warranted.

DOI： 10.1111/j.1525-1438.2008.01192.x

Web of Science

researchmap

[Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].

Shoji Nagao, Naoki Okimoto, Atsushi Hongo, Yasushi Mizutani, Junichi Kodama, Mitsuo Yoshinouchi, Yuji Hiramatsu, Takafumi Kudo

Gan to kagaku ryoho. Cancer & chemotherapy 30 ( 2 ) 243 - 9 2003.2

Language：Japanese Publishing type：Research paper (scientific journal)

To evaluate the validity of administration of paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients with gynecologic cancer, we explored the efficacy and safety of these regimens. From October 1, 1998 to September 30, 2001, we administered paclitaxel and carboplatin with or without THP-ADR pursuant to the chart we prepared originally as first line chemotherapy in patients with gynecologic cancer. Eleven elderly patients (age > 70 years) and 62 younger patients (age < 70 years) were entered into the present study. Paclitaxel was administered as a 3-hour intravenous (i.v.) infusion at dosages of 135 to 180 mg/m2 immediately followed by carboplatin over 60 minutes at dosages of area under the curve (AUC) 3 to 5, administered intravenously or intraperitoneally. We observed grade 3/4 anemia more frequently in elderly patients receiving the regimen including paclitaxel and carboplatin without THP-ADR (9% v.s. 47%, p < 0.0001). Grade 3/4 anemia (10% v.s. 22%, p = 0.02) and grade 3/4 thrombocytopenia (7% v.s. 22%, p = 0.007), febrile neutropenia (14% v.s. 44%, p = 0.02) also occurred more frequently in elderly patients receiving the regimen including paclitaxel and carboplatin with THP-ADR. The overall response rates were equivalent among elderly and younger patients (69% and 78%), respectively. The regimen consisting of paclitaxel and carboplatin without THP-ADR was applied safely to elderly patients.

PubMed

researchmap

[The effect of L-Glutamine and Shakuyaku-Kanzo-to for paclitaxel-induced myalgia/arthralgia].

Kosei Hasegawa, Yasushi Mizutani, Hiroyuki Kuramoto, Shoji Nagao, Hisashi Masuyama, Atsuhi Hongo, Jyunichi Kodama, Mitsuo Yoshinouchi, Yuji Hiramatsu, Takafumi Kudo, Hiroyuki Okuda

Gan to kagaku ryoho. Cancer & chemotherapy 29 ( 4 ) 569 - 74 2002.4

Language：Japanese Publishing type：Research paper (scientific journal)

Myalgia/arthralgia is a crucial side effect of paclitaxel, and may become the major dose-limiting side effect. However, this is a situation where there is little effective preventive treatment. L-Glutamine was reported as a neuroprotective agent for vincristine-induced neurotoxicity. In Japan, there have been reports on steroid and Shakuyaku-Kanzou-to (a herbal medicine) for paclitaxel-induced myalgia/arthralgia. This study aimed to compare the effect of L-Glutamine and Shakuyaku-Kanzou-to, and to discuss the validity of these agents for the paclitaxel-induced myalgia/arthralgia. Our results suggested that Shakuyaku-Kanzou-to showed no remarkable effects against paclitaxel-induced myalgia/arthralgia as had been reported before; however, both L-Glutamine and Shakuyaku-Kanzou-to decreased the duration of grade 2 toxicity (CALGB Expanded Common Toxicity Criteria) in comparison with those who were not treated. L-Glutamine and Shakuyaku-Kanzou-to might therefore a preventive effect against moderate or severer myalgia/arthralgia during paclitaxel-treated chemotherapy. Further trials are needed to confirm the value of these drugs.

PubMed

researchmap

Rapid and sensitive detection of physical status of human papillomavirus type 16 DNA by quantitative real-time PCR. Reviewed International journal

Shoji Nagao, Mitsuo Yoshinouchi, Yasunari Miyagi, Atsushi Hongo, Junichi Kodama, Sachio Itoh, Takafumi Kudo

Journal of clinical microbiology 40 ( 3 ) 863 - 7 2002.3

Language：English Publishing type：Research paper (scientific journal)

A rapid quantitative real-time PCR method was employed to quantify the copy number of E2 and E6 genes for analysis of the physical status of human papillomavirus type 16 (HPV-16) DNA. Significant differences with respect to both copy numbers were found when more than 40% of HPV-16 DNA was integrated with disruption of the E2 gene in an experimental model. The physical status of HPV-16 DNA in 50 clinical samples was exclusively episomal in 21 cases (42%), concomitant in 14 cases (28%), and integrated in 15 cases (30%). The prevalence of integrated and/or concomitant forms of HPV-16 DNA increased with progression of cervical disease. Four of 11 cervical intraepithelial neoplasia involved integrated forms of HPV-16 DNA partially or exclusively. This rapid, sensitive technique is useful in the analysis of the physical status of HPV DNA.

PubMed

researchmap

腹腔鏡補助下膣式子宮全摘術の難易度推定のための術前診断スコア (LAVH Score)

松本貴, 倉本博行, 矢野真理, 山本寄人, 長尾昌二, 兵頭慎治, 木花敏雅, 野田清史, 石井修平, 森巍

日本産科婦人科内視鏡學會雜誌 = The journal of the Japan Endoscopy Society of Obstetrics and Gynecology 14 ( 1 ) 121 - 124 1998.12

当院における腹腔鏡補助下腟式子宮全摘術(LAVH)の検討(TVH施行例との比較とLAVHの意義について)

松本貴, 松岡亮平, 今井香里, 長尾昌二, 片山富博, 森巍

日本産科婦人科内視鏡學會雜誌 = The journal of the Japan Endoscopy Society of Obstetrics and Gynecology 12 ( 1 ) 83 - 86 1996.12

　 PREV - NEXT 　

< NAGAO Shoji >

Papers - NAGAO Shoji